Novalek Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 12-12-2024
- Paid Up Capital ₹ 0.50 M
as on 12-12-2024
- Company Age 18 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2022)
- Profit -162.91%
(FY 2022)
- Ebitda -272.40%
(FY 2022)
- Net Worth -19.10%
(FY 2022)
- Total Assets -0.02%
(FY 2022)
About Novalek Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Anu Kumari, Shashi Singh, Jyoti Loomba, and One other member serve as directors at the Company.
- CIN/LLPIN
U24231TG2006PTC120839
- Company No.
120839
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Jan 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Novalek Pharmaceutical?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anu Kumari  | Director | 09-Jan-2006 | Current |
| Shashi Singh | Director | 01-Oct-2012 | Current |
| Jyoti Loomba | Director | 01-Oct-2012 | Current |
| Sanjay Prabhakar | Director | 09-Jan-2006 | Current |
Financial Performance and Corporate Structure Insights of Novalek Pharmaceutical.
Novalek Pharmaceutical Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 162.91% decrease in profit. The company's net worth observed a substantial decline by a decrease of 19.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Novalek Pharmaceutical?
In 2020, Novalek Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Jodas Expoim Private LimitedActive 18 years 3 monthsShashi Singh and Jyoti Loomba are mutual person
Jodas Consumer Care Private LimitedActive 7 years 1 monthShashi Singh and Jyoti Loomba are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Novalek Pharmaceutical?
Unlock and access historical data on people associated with Novalek Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Novalek Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Novalek Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
